Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B013 plus Nab-Paclitaxel in Advanced TNBC
NCT05555706Phase 3Completed
- Sponsor
- Shanghai Cross-linked Pharmaceutical Research and Development
- Start
- Dec 2022
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of B-013 in triple-negative breast cancer (TNBC), sponsored by Shanghai Cross-linked Pharmaceutical Research and Development. Started Dec 2022; status: completed.
02
Drugs
B-013
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05555706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555706.